company background image

MINAPHARM Pharmaceuticals CASE:MIPH Stock Report

Last Price


Market Cap







06 Dec, 2023


Company Financials

MINAPHARM Pharmaceuticals

CASE:MIPH Stock Report

Mkt Cap: ج.م2.6b

MIPH Stock Overview

MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East.

MIPH fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance1/6
Financial Health3/6

MINAPHARM Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MINAPHARM Pharmaceuticals
Historical stock prices
Current Share Priceج.م236.27
52 Week Highج.م252.00
52 Week Lowج.م128.50
1 Month Change15.83%
3 Month Change18.64%
1 Year Change69.11%
3 Year Change193.50%
5 Year Change179.61%
Change since IPO2,498.97%

Recent News & Updates

Recent updates

Shareholder Returns

MIPHEG PharmaceuticalsEG Market

Return vs Industry: MIPH exceeded the EG Pharmaceuticals industry which returned 20.2% over the past year.

Return vs Market: MIPH underperformed the EG Market which returned 71.5% over the past year.

Price Volatility

Is MIPH's price volatile compared to industry and market?
MIPH volatility
MIPH Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement6.5%
10% most volatile stocks in EG Market10.0%
10% least volatile stocks in EG Market4.5%

Stable Share Price: MIPH is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: MIPH's weekly volatility (5%) has been stable over the past year.

About the Company

1958n/aWafik El Bardissi

MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Corneregel fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Netophtiole plus eye drops; Extrauma cream; and Ophtatrov and Optatrov plus. It also provides Ferroduonal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, Pixcolt, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules.

MINAPHARM Pharmaceuticals Fundamentals Summary

How do MINAPHARM Pharmaceuticals's earnings and revenue compare to its market cap?
MIPH fundamental statistics
Market Capج.م2.61b
Earnings (TTM)ج.م460.73m
Revenue (TTM)ج.م4.00b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MIPH income statement (TTM)
Cost of Revenueج.م2.40b
Gross Profitج.م1.60b
Other Expensesج.م1.14b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date


Earnings per share (EPS)41.64
Gross Margin39.98%
Net Profit Margin11.51%
Debt/Equity Ratio90.8%

How did MIPH perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio